What is the price-to-earnings ratio of Ucb?
The price-earnings ratio of Ucb is currently 4.3.
Ucb P/S 2024
Ucb P/S
4.3
Ticker
UCB.BR
ISIN
BE0003739530
WKN
852738
As of Oct 1, 2024, Ucb's P/S ratio stood at 4.3, a 43.33% change from the 3 P/S ratio recorded in the previous year.
The Ucb P/S history
Ucb Aktienanalyse
What does Ucb do?
The company UCB SA is a Belgian pharmaceutical company that was founded in 1928 and is now active worldwide. The business model of UCB SA is based on the discovery and development of medications for severe diseases. The core competencies of the company are in neurology, immunology, and cardiology. In the history of UCB SA, there are several milestones. In 1961, UCB SA succeeded in synthesizing antihistamines, which marked the beginning of the development of medications for allergic diseases. In the 1990s, UCB SA began to focus on the development of medications for the treatment of epilepsy and Parkinson's disease. In the 2000s, UCB SA acquired several companies, expanding its portfolio of medications and its geographic reach. The company operates three different divisions: pharmaceuticals, biopharmaceuticals, and specialty chemicals. In the pharmaceuticals division, UCB SA develops and distributes medications for the treatment of epilepsy, Parkinson's disease, and autoimmune diseases such as rheumatoid arthritis and lupus. UCB SA's biopharmaceutical division focuses on researching antibodies for the treatment of various diseases such as cancer and multiple sclerosis. In the specialty chemicals division, UCB SA produces chemical products such as solvents and paints. The company offers a wide range of products tailored to the needs of patients with various diseases. One example of a well-known product from UCB SA is Keppra, a medication for the treatment of epilepsy. Keppra is one of the most prescribed medications for epilepsy and has helped improve the lives of millions of patients. Another example is Cimzia, a medication for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Cimzia belongs to a new generation of medications that aim to selectively influence the immune system and thus inhibit inflammation. UCB SA places great value on innovation and constantly researches new medications and therapies. The company has a strong research and development team with over 3,000 employees and invests approximately 25% of its revenue annually in the research and development of new medications. Overall, UCB SA is an innovative and successful pharmaceutical company with a broad portfolio of medications and a strong commitment to the quality of the products developed. The company is dedicated to improving the lives of patients with severe diseases and remains a key player in the global pharmaceutical industry in the long term. Ucb ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Ucb's P/S Ratio
Ucb's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Ucb's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Ucb's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Ucb’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Ucb stock
How has the price-earnings ratio of Ucb changed compared to last year?
The price-to-earnings ratio of Ucb has increased by 43.33% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Ucb high compared to other companies?
Yes, the price-to-earnings ratio of Ucb is high compared to other companies.
How does an increase in the price-earnings ratio of Ucb affect the company?
An increase in the price-earnings ratio of Ucb would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Ucb affect the company?
A decrease in the price-earnings ratio of Ucb would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Ucb?
Some factors that influence the price-earnings ratio of Ucb are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Ucb pay?
Over the past 12 months, Ucb paid a dividend of 1.33 EUR . This corresponds to a dividend yield of about 0.82 %. For the coming 12 months, Ucb is expected to pay a dividend of 1.36 EUR.
What is the dividend yield of Ucb?
The current dividend yield of Ucb is 0.82 %.
When does Ucb pay dividends?
Ucb pays a quarterly dividend. This is distributed in the months of May, May, May, May.
How secure is the dividend of Ucb?
Ucb paid dividends every year for the past 26 years.
What is the dividend of Ucb?
For the upcoming 12 months, dividends amounting to 1.36 EUR are expected. This corresponds to a dividend yield of 0.84 %.
In which sector is Ucb located?
Ucb is assigned to the 'Health' sector.
Wann musste ich die Aktien von Ucb kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Ucb from 4/30/2024 amounting to 1.36 EUR, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.
When did Ucb pay the last dividend?
The last dividend was paid out on 4/30/2024.
What was the dividend of Ucb in the year 2023?
In the year 2023, Ucb distributed 1.3 EUR as dividends.
In which currency does Ucb pay out the dividend?
The dividends of Ucb are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Ucb
Our stock analysis for Ucb Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ucb Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
